Overview

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD

Status:
NOT_YET_RECRUITING

Trial end date:
2031-06-10

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD), as well as to assess the safety and tolerability, of inebilizumab in pediatric participants with IgG4-RD.

Phase:

PHASE2

Details

Lead Sponsor:

Amgen

Treatments:

inebilizumab